| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $1.7M | -48.0% |
| SG&A Expense | $8.8M | +86.2% |
| Net Income | -$10.4M | -33.0% |
| EPS (Basic) | -$1.35 | -164.7% |
| EPS (Diluted) | -$1.35 | -164.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $6.3M | +124.0% |
| Short-term Investments | $4.7M | — |
| Current Assets | $11.1M | +282.9% |
| Total Assets | $11.1M | +279.5% |
| Current Liabilities | $702K | -2.9% |
| Total Liabilities | $702K | -2.9% |
| Stockholders' Equity | $10.4M | +372.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$4.7M | +16.2% |
| Financing Cash Flow | $8.2M | +115.7% |